

Declarations of Interest

Speakers at College meetings are asked to declare any interests which they might have relating to their presentations. A declaration of interest in no way implies that the individual has actually been influenced by his or her secondary interest.

Forename	Surname	Session	Declaration
Melanie Amna	Abas	S13	This speaker has no interests to declare
Dasal	Abayaratne	S36	This speaker has no interests to declare
Anis	Ahmed	MC9	This speaker has no interests to declare
Nahida	Ahmed	S39	This speaker has no interests to declare
Suhana	Ahmed	S5	This speaker has no interests to declare
Alka	Ahuja	S2	This speaker has no interests to declare
Nadira	Awal	S35	This speaker has no interests to declare
Tom	Ayers	S27	This speaker has no interests to declare
John	Baker	MC4	This speaker has no interests to declare
Thomas	Barnes	S34, S50	This speaker has no interests to declare
Hadiza	Bawa-Garba	S31	This speaker has no interests to declare
Candace	Bedu-Mensah	MC6	This speaker has no interests to declare
Stephanie	Behan	MC5	This speaker has no interests to declare
Stephanie	Behrman	S35	This speaker has no interests to declare
Francis	Bennett	S36	This speaker has no interests to declare
Allan	Beveridge	S7	This speaker has no interests to declare
Rahul	Bhattacharya	S47	This speaker has no interests to declare
Paul	Blenkiron	S55	This speaker has no interests to declare
Michael	Bloomfield	S42	This speaker is director and shareholder of Bloomfield Health Holdings Limited. Their husband is a director and shareholder of Bloomfield Health Holdings Limited.
Matthew	Burke	S40	This speaker has no interests to declare
Wendy	Burn	MC10, S5	This speaker has no interests to declare
Veronica	Cabrera	TC1	This speaker has no interests to declare
Jonathan	Campion	S49	This speaker has no interests to declare
Katherine	Cannon	S35	This speaker has no interests to declare
Alan	Carson	TC1	This speaker has no interests to declare
Guy	Chadwick	MC2	This speaker has no interests to declare
Sam	Chamberlain	S18, S24	This speaker has received honoraria for journal editorial work at Elsevier
Lucy	Chappell	KN15	This speaker has no interests to declare
Horatio	Clare	S7	This speaker has no interests to declare
Pip	Clery	S36	This speaker has no interests to declare
Eleanor	Cooke	S36	This speaker has no interests to declare

Christoph	Correll	S16	This speaker has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatrix. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma and Quantic.
Samuele	Cortese	S33, S51	This speaker has no interests to declare
Ken	Courtenay	S38	This speaker was sponsored to speak at a conference in Girona, Spain on 19 May 2023. The presentation was on medication in people with intellectual disabilities.
Helen	Crimlisk	S9	This speaker has no interests to declare
Ilana	Crome	S3	Drug Science receives an unrestricted educational grant from a consortium of medical cannabis companies to further its mission, that is the pursuit of an unbiased and scientific assessment of drugs regardless of their regulatory class.
Suzy	Crowe	S35	This speaker has no interests to declare
Stuart	D'arch Smith	S36	This speaker has no interests to declare
Caroline	Dalton	S30	This speaker has no interests to declare
Jermaine	Dambi	S13	This speaker has no interests to declare
Ananta	Dave	MC6	This speaker has no interests to declare
Conor	Davidson	S38, S54	This speaker has no interests to declare
Holly	Davis-Bollard	S55	This speaker has no interests to declare
Paola	Dazzan	S16	This speaker has no interests to declare
John	De Pury	S20	This speaker has no interests to declare
Quinton	Deeley	S21	This speaker has no interests to declare

Arianna	Di Florio	S35	This speaker has no interests to declare
A A A Manik	Djelantik	S17	This speaker has no interests to declare
Mary	Docherty	S34	This speaker has no interests to declare
Laura	Dockrill	KN2	This speaker has no interests to declare
Clare	Dolman	S29	This speaker has no interests to declare
James	Downs	MC5	This speaker has no interests to declare
Niamh	Eastwood	S3	This speaker has no interests to declare
Jessica	Eccles	MC2	This speaker has no interests to declare
Saeed	Farooq	S12	The research presented in this symposium is funded by the NIHR. This speaker has previously received honorarium as advisor as well as speakers fees from the following pharmaceuticals on different topics: CNX Therapeutics, Novartis, Lundbeck, Otsuka and , Sunovion. None of these funding is in relation to the presentation for this symposium.
Seena	Fazel	S52, TC1	This speaker has received funding from the Wellcome trust in 2012 to examine links between head injury and offending as part of a larger fellowship that examined different neuropsychiatric diagnoses
Mina	Fazel	S6	This speaker has no interests to declare
Kevin	Fenton	S49	This speaker has no interests to declare
Blossom	Fernandes	S6	This speaker has received funding from the Wellcome Trust
Naomi	Fineberg	S42	This speaker has received research funding from the NIHR, EU COST Action, Horizon Europe, University of Hertfordshire, Orchard. They have received payment for lectures from the Global Mental Health Academy and World Psychiatric Association (WPA). They have received travel expenses to attend meetings remunerated by the ECNP, BAP, WPA, RCPsych, CINP. They are a Board member of Orchard and provides expert opinion to the MHRA on the psychopharmacology of mental disorders. They are Secretary, International College of Obsessive Compulsive Spectrum Disorders. They lead a NHS England OCD/BDD treatment service.
Joseph	Firth	S28	This speaker has no interests to declare
Robert	Flanagan	MC11	This speaker has no interests to declare
Peter	Fonagy	MC3	This speaker has no interests to declare

Tamsin	Ford	S11, S6	This speaker has no interests to declare
Tim	Foskett	S22	This speaker has no interests to declare
Sophia	Frangou	S51	This speaker has no interests to declare
Ashley	Fulwood	S25	This speaker has no interests to declare
Carolyn	Fyall	MC9	This speaker has no interests to declare
Clare	Gerada	S31	This speaker has no interests to declare
Tania	Gergel	S29, S53	This speaker has no interests to declare
Paul	Gilluley	S39	This speaker has no interests to declare
Guy	Goodwin	S50, S46	This speaker has no interests to declare
Jon	Grant	S24	This speaker has received research grants from the following companies paid to the University of Chicago: Janssen, Biohaven, and Boehringer-Ingelheim pharmaceuticals
Amy	Green	MC5	
Philipa	Greenfield	S8	This speaker has no interests to declare
Julia	Griem	S48	This speaker has no interests to declare
Sumeet	Gupta	S25	This speaker has no interests to declare
Else	Guthrie	S4	The presentation is based upon two studies both funded by NIHR. One is a trial funded by HTA and the other is a programme of research funded by PfAR.
Ian	Hall	S43	This speaker has no interests to declare
Katie	Hall	S36	This speaker has no interests to declare
Deborah	Harman	S22	This speaker has no interests to declare
Adrian	Heald	S30	This speaker has no interests to declare
Simon	Heyland	S4	This speaker has no interests to declare
Emily	Hird	S40	This speaker has no interests to declare
Nathan	Huneke	S40	This speaker has no interests to declare
Chris	Hollis	KN5	This speaker was an expert advisor to NICE (unpaid) for the Early Value Assessment of digital CBT for low mood and anxiety in children and young people. 2018-20: They received reimbursement as a member of the external advisory board for Kooth.
Rob	Howard	KN11	This speaker has no interests to declare
Mike	Hunter	S9	This speaker has no interests to declare
Nusrat	Husain	S11	This speaker has no interests to declare
Artemis	Igoumenou	S23	This speaker has no interests to declare
Chineze	Ivenso	S45	This speakers has received fees for consultancy for participating in virtual advisory board meetings organised by Biogen and received sponsorship from Biogen to attend a meeting
Felice	Jacka	KN9	This speaker has written two books for commercial publication

Sameera	Jahagirdar	S22	This speaker has no interests to declare
Sharif	Jaker	MC9	This speaker has no interests to declare
Adrian	James	MC8, MC3, S49, KN1	This speaker has no interests to declare
Benjamin	Janaway	S5	This speaker has no interests to declare
Channa	Jayasena	S26	This speaker has no interests to declare
Sujeet	Jaydeokar	S38, S23	This speaker has no interests to declare
Gemma	Johns	S2	This speaker has no interests to declare
Ian	Jones	S29	This speaker has no interests to declare
Kenneth	Kaufman	S39, KN8	This speaker has no interests to declare
Harry	Kennedy	KN12	This speaker has no interests to declare
Rose Anne	Kenny	KN16	This speaker has no interests to declare
Kay	Khan	S27	This speaker has no interests to declare
Helen	Killaspy	S8	This speaker has no interests to declare
Simon	Kitchen	S29	This speaker works for Bipolar UK which has an interest in improving outcomes for people affected by bipolar.
Brian	Kirkpatrick	S41	This speaker is CEO and part owner of Quantic Innovations (QI), which provides services related to digital phenotyping of people with psychiatric disorders; QI has contracts with Karuna Therapeutics and Sunovion. He receives licensing royalties from ProPhase for use of the Brief Negative Symptom Scale (BNSS) by for-profit groups; these fees are donated to the Brain and Behavior Research Foundation. In the last three years he has also received honoraria and travel support from ProPhase for training pharmaceutical company raters on the BNSS; consulting fees and/or travel support from Lundbeck, Acadia, ProPhase, Otsuka, and Minerva Neurosciences; fees from anonymized investors through Guideposts and Decision Resources Group; and an honorarium from Otsuka for preparation of educational materials.
Steve	Kisely	S39	This speaker has no interests to declare
Agnieszka	Klimowicz	S44	This speaker works in private practice, including as an rTMS consultant. They use rTMS in some instances in perinatal patients.
Swapna	Kongara	MC6	This speaker has no interests to declare
Jayashri	Kulkarni	S35	This speaker has no interests to declare
Manoj	Kumar	S39	This speaker has no interests to declare

Jimmy	Lee	S41	This speaker has no interests to declare
Belinda	Lennox	S32	This speaker has no interests to declare
Petros	Levounis	KN7	This speaker has no interests to declare
Glyn	Lewis	S53, S42	This speaker has received funding from the NIHR, Wellcome Trust and UKRI that has supported they're research programme. They have been funded to attend the ECNP Conference Barcelona in October 2023 to present and discuss their research findings.
Lucia	Li	TC1	This speaker has no interests to declare
Anne	Lingford-Hughes	S3	This speaker is Chair of Addiction Mission, OLS, UK Government. Research support from GSK, Consultancy (paid into University account) Astra Zeneca, Indivior; (unpaid) Nodthera.
Kate	Lorrimer	S27	This speakers partner is in the Senior Management Team at RCPsych
James	MacCabe	S12	This speaker has received research funding from Galenicap Consultancy fees for LB Pharma
Joan	Marsh	S18, S51	This speaker hold shares in, Elsevier, a commercial science publisher
Emma	McAllister	MC4	This speaker has no interests to declare
Hamish	McAllister-Williams	S1	This speaker has recieved honoraria for speaking or consultation fees; sponsorship for attending meetings: LivaNova, Janssen-Cilag, Lundbeck, Novartis, Boehringer Ingelheim, Sothema
Robert	McCutcheon	MC1	This speaker has received speaking fees/served on advisory boards of Otsuka, Karuna and Janssen and is director of a company which hosts psymatik.com
Emma	McLachlan	S37	This speaker has no interests to declare
Sarah	Mee	S50	This speaker has no interests to declare
Helen	Minnis	MC2	This speaker has no interests to declare
Rajesh	Mohan	MC8, MC7	This speaker has no interests to declare
Peter	Molyneux	MC10	This speaker has no interests to declare
Hannah	Moore	S28	This speaker has no interests to declare
Armida	Mucci	S41	This speaker has received fees for consultancy, outside the present work, from the following companies: Angelini, Pierre Fabre, Rovi Pharma and Boehringer Ingelheim
Santosh	Mudholkar	MC7	This speaker has no interests to declare
Ulrich	Muller-Sedgwick	S33	This speaker received a consultancy fee from Takeda (UK) in 2023

Robin	Murray	S16, KN4	This speaker has received payments for non-promotional lectures for Janssen, Lundbeck, Otsuka and Rovia
Graham	Murray	S12	This speaker has received fees for consultancy, consults for IESO Digital Health
Catherine	Mutisya	S39	This speaker has no interests to declare
Nyembezi Faith	Ndebele	S2	This speaker has no interests to declare
Nikki	Nabavi	S18	This speaker has no interests to declare
Humphrey	Needham-Bennett	S14	This speaker has no interests to declare
Marion	Neffgen	S36	This speaker has no interests to declare
Nafeesa	Nizami	S4	This speaker has no interests to declare
Kelly	Norwood	S17	This speaker has no interests to declare
Mary-Frances	O'Connor	S17	This speaker has given a number of talks this year to palliative care, hospices, and bereavement support organizations for which they have received modest honorariums. They also published a trade book with HarperCollins, and received an advance and royalties.
Donal	O'Shea	KN8	This speaker has received honoraria for talks from Novo Nordisk, Menarini, Lilly
Edoardo G.	Ostinelli	S53	This speaker has no interests to declare
Marcin	Ostrowski	S9	This speaker has no interests to declare
Femi	Oyebode	S7	This speaker has no interests to declare
Lisa	Page	S36	This speaker has no interests to declare
Smita	Pandit	MC6, S8	This speaker has no interests to declare
Carol	Paton	S34	This speaker has no interests to declare
Ruth	Pauli	S48	This speaker has no interests to declare
Edward	Penington	S32	This speaker has no interests to declare
Luca	Pellegrini	S24	This speaker has no interests to declare
Wendy	Phillips	S21	This speaker does medicolegal work where experience in FND is required
Toby	Pillinger	S30	This speaker has provided educational talks for Lundbeck, Otsuka, and Recordati.
Maggie	Rae	S28	This speaker has no interests to declare
Atif	Rahman	KN6	This speaker's institution has received funding from the Wellcome Trust, UK, NIHR UK, and NIMH USA to conduct some of the research I will be presenting. This will be acknowledged in their presentation.
Fiona	Raje	S55	This speaker has no interests to declare
Thara	Rangaswamy	KN10	This speaker has no interests to declare
Tony	Rao	S14	This speaker has no interests to declare

Abdul	Raof	S54	This speaker has no interests to declare
Vanessa	Raymont	S45	This speaker has no interests to declare
Suzanne	Reeves	S37	This speaker has no interests to declare
Gavin	Reynolds	S30	This speaker has received support from Merck/MSD Pharmaceuticals for a research project Consultancy fees from Boehringer Ingelheim and Recordati Pharmaceuticals
Jemma	Reid	S25	This speaker has no interests to declare
Jonathan	Richardson	S47	This speaker has no interests to declare
Rosa	Roberts	S36	This speaker has no interests to declare
Callum	Ross	S26	This speaker has no interests to declare
Ashok	Roy	S54	This speaker has no interests to declare
John	Russell	S43	This speaker has no interests to declare
Howard	Ryland	S52, S47	This speaker has no interests to declare
Amrit	Sachar	MC8	This speaker is employed by West London NHS Trust. Their talk is about this trust and may have an impact on external perception about the trust and attract staff to apply for jobs. They are the Lead for Medical Workforce Race Equality Standards in their trust and is an Equality Champion in the RCPsych and is the incoming Presidential Lead for Equality and Equity
Paddakara	Saju	S4	This speaker has no interests to declare
Musa	Sami	S10	This speaker has no interests to declare
Brendan	Sargent	TC1	This speaker has no interests to declare
Inder	Sawhney	S19	This speaker has no interests to declare
Lon	Schneider	S37	Within a 36 month time frame, Dr. Schneider reports grants from NIH R01 AG054434, P30 AG066530, R01 AG062687, R01 AG051346, R01 AG055444, P01 AG02350, R01 AG053267, R01 AG074983, R01 AG063826, State of California CADC 15-10291; grants and personal fees from Eli Lilly, grants and personal fees from Roche/Genentech; grants/contracts from Eisai, Biogen, and Biohaven; grants from Washington University, St. Louis/ NIA DIAN-TU, grants from UC San Diego ADCS, personal fees from Neurim, Ltd, Cognition Therapeutics, Immunobrain Checkpoint, Ltd, Alpha-cognition, BioVie, Cortexyme, AC Immune, Athira, GW Research, Merck, Otsuka, Pharmatrophix, Lundbeck, Novo Nordisk, Vivli.org, outside the submitted

			work; and The Della Martin Foundation endowment.
Dan	Scorer	S19	This speaker is employed by Royal Mencap Society, a charity, and will be representing the view of the organisation in the presentation
Jane	Sedgwick-Muller	S33	This speaker is Executive Committee Member: UK Adult ADHD Network. Professional advisory committee member of ADDISS: The National Charity for ADHD Information & Support. Educational grant from Royal College of Nursing Foundation. Speakers honorarium from Takeda Pharma., Flynn Pharma., MEDICE Pharma., PATOSS, BDA, RANSTAD.
Nisha	Shah	S8	This speaker has no interests to declare
Hannah	Shotton	S15	This speaker has no interests to declare
Siham	Sikander	S13	This speaker has no interests to declare
Gagandeep	Singh	S25	This speaker has no interests to declare
Om Prakash	Singh	S51	This speaker has no interests to declare
Vimal	Sivasanker	S34	This speaker has no interests to declare
Shubulade	Smith	MC9, S49, KN14	This speaker has no interests to declare
Iris	Sommer	MC1	This speaker has no interests to declare
Oliver	Standing	S10	This speaker has no interests to declare
Tim	Stevens	S14	This speaker has no interests to declare
Brendan	Stone	S27	This speaker has no interests to declare
Andre	Strydom	S23	This speaker has received funding for research and consulted for AC Immune, and hold a tender from NHSE for the LeDeR programme. I am investigator on industry sponsored trials
Devin	Terhune	S21	This speaker has no interests to declare
Louise	Theodosiou	S20	This speaker has no interests to declare
Alex	Thomson	MC4	This speaker has no interests to declare
Christy	Thozar	MC6	This speaker has no interests to declare
Phil	Timms	S55	This speaker has no interests to declare
Anneka	Tomlinson	MC1	This speaker has received funds for a member of staff, funds for research and fees for consultancy
Derek	Tracy	S18	This speaker has no interests to declare
Samuel	Tromans	S19	This speaker is employed by the University of Leicester, and has an honorary contract with Leicestershire Partnership NHS Trust. He was Chief Investigator for an NIHR-supported study of autism prevalence in psychiatric

			hospitals (2018-2021). He has also received research funding from the Baily Thomas Charitable Fund, National Institute for Health and Care Research, the Wellcome Trust, and NHS Digital (via the Department of Health and Social Care).
John	Tully	S48	This speaker has no interests to declare
Caroline	Turriff	S10	This speaker has no interests to declare
Himanshu	Tyagi	S44	This speaker has no interests to declare
Jon	Van Niekerk	MC10	This speaker has no interests to declare
Chris	Walsh	S43	This speaker has no interests to declare
Paul	Warren	TC1	This speaker has no interests to declare
Daniel	Whiting	S52	This speaker has no interests to declare
Nicola	Wiles	S1	This speaker was Chief Investigator of the NIHR HTA-funded CoBaIT trial (CBT as an adjunct to pharmacotherapy for TRD in primary care: ISRCTN38231611), and is an author of the Cochrane Review of psychological therapies for TRD (and two included studies) discussed in this presentation.
Ryan	Williams	S32	This speaker has no interests to declare
Richard	Williams	S11	This speaker has no interests to declare
Nolan	Williams	S44	This speaker has no interests to declare
Anne	Worrall-Davies	S23	This speaker has no interests to declare
Allan	Young	S29, S46, KN13	This speaker is employed by King's College London; Honorary Consultant South London and Maudsley NHS Foundation Trust (NHS UK) Editor of Journal of Psychopharmacology and Deputy Editor, BJPsych Open, Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders: Astrazenaca, Boehringer Ingelheim, Eli Lilly, LivaNova, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, COMPASS, Sage, Novartis, Neurocentrx Principal Investigator in the Restore-Life VNS registry study funded by LivaNova. Principal Investigator on ESKETINTRD3004: "An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression." Principal Investigator on "The Effects of Psilocybin on Cognitive Function in Healthy Participants" Principal Investigator on "The Safety and Efficacy of Psilocybin in

			<p>Participants with Treatment-Resistant Depression (P-TRD)" UK Chief Investigator for Compass; COMP006 & COMP007 studies UK Chief Investigator for Novartis MDD study MIJ821A12201 Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK) EU Horizon 2020 No shareholdings in pharmaceutical companies</p>
Adam	Zeman	TC1	This speaker has no interests to declare